AnaptysBio, Inc.
dostarlimab
untreated stage II/III dMMR/MSI-H locally advanced rectal cancer
Countdown
86days
Phase 2 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 2 trial results for dostarlimab in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Data expected in Q4 2026”